Dr. Raajit Chanana

Dr Raajit Chanana is a senior medical oncologist and haemato-oncologist in Delhi with 16 years of experience in the diagnosis and treatment of solid tumours, haematological malignancies, and blood cancers.

He is the Director of Medical Oncology at Dharamshila Narayana Superspeciality Hospital, Delhi and holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai, India's foremost dedicated cancer centre, along with a Certification in Advanced Management of Oncological Disease from Harvard Medical School, Boston, USA (2025) and ESMO certification from the European Society for Medical Oncology.

Patients seeking expert cancer treatment in Delhi, trusted immunotherapy in Delhi, or advanced targeted therapy and precision oncology in Delhi will find Dr Chanana at Dharamshila Narayana Superspeciality Hospital, Vasundhara Enclave and Oncare Cancer Care Centre, Sector 41.

He was awarded the Patient Centric Innovator Award at the 7th Cancer Summit and Awards 2026 and the Best Oncologist of the Year by IBA 2024.

He consults in English and Hindi, ensuring clear communication for patients from across north India.

Specialty Areas and Treatments

Dr Raajit Chanana delivers comprehensive medical oncology and haematological oncology care through evidence-based, personalised, and multidisciplinary treatment approaches with a strong focus on precision medicine and clinical trials.

Treatment Modalities

Dr Chanana offers the full spectrum of systemic cancer treatment approaches:

• Chemotherapy intravenous, intrathecal, oral, and metronomic
• Immunotherapy checkpoint inhibitors and immune-based agents
• Targeted Therapy and Precision Medicine for molecularly profiled cancers
• Personalised Cancer Treatment based on tumour genomics and biomarkers
• Hormone Therapy for hormone-sensitive malignancies
• Antibody Drug Conjugates (ADC) for advanced solid tumours
• HIPEC (Hyperthermic Intraperitoneal Chemotherapy) for peritoneal malignancies
• PIPAC Treatment for advanced peritoneal surface malignancies
• PICC Line Insertion for long-term chemotherapy access

Lung Cancer in Delhi

Dr Chanana has published research on targeted therapy in lung cancer including ALK-positive NSCLC and ROS1 rearranged NSCLC, with work presented at ESMO Asia 2017:

• Non-Small Cell Lung Cancer (NSCLC) EGFR, ALK, ROS1, RET targeted therapy
• Immunotherapy for Lung Cancer including subcutaneous checkpoint inhibitors
• Small Cell Lung Cancer chemotherapy and immunotherapy
• Malignant Pleural Mesothelioma systemic management with published outcomes data
• Stage III and IV Lung Cancer combination systemic management

Breast Cancer in Delhi

Dr Chanana manages all breast cancer subtypes with published and educational content on targeted therapies:

• HER2 Positive Breast Cancer trastuzumab, pertuzumab, and ADC-based regimens
• Triple Negative Breast Cancer chemotherapy and immunotherapy
• Hormone Receptor Positive Breast Cancer endocrine therapy and CDK inhibitors
• Metastatic Breast Cancer systemic management
• Early Stage Breast Cancer adjuvant and neoadjuvant chemotherapy

Gastrointestinal and Hepatobiliary Cancers in Delhi

Dr Chanana manages GI and hepatobiliary malignancies through evidence-based systemic approaches:

• Gastric and Gastroesophageal Junction Cancer
• Colorectal Cancer FOLFOX, FOLFIRI, bevacizumab, cetuximab
• Oesophageal Cancer chemotherapy and targeted therapy
• Hepatocellular Carcinoma sorafenib and immunotherapy
• Pancreatic Cancer gemcitabine-based systemic management
• Gallbladder and Cholangiocarcinoma systemic management

Genitourinary Cancers in Delhi

Dr Chanana manages genitourinary cancers through targeted and immunotherapy-based approaches with academic engagement in urothelial carcinoma treatment:

• Urothelial and Bladder Cancer including Enfortumab Vedotin and immunotherapy
• Prostate Cancer hormone therapy and chemotherapy
• Kidney Cancer targeted therapy and immunotherapy
• Testicular Cancer BEP and salvage regimens

Head and Neck Cancer in Delhi

Dr Chanana has published research on systemic treatment outcomes in head and neck cancers including supraglottic and HPV-negative oropharyngeal cancers:

• Oropharyngeal and Laryngeal Cancer chemotherapy and immunotherapy
• QOL-focused Treatment Protocols for recurrent and metastatic head and neck cancer with published clinical trial data

Haematological Malignancies in Delhi

Dr Chanana manages the full spectrum of haematological cancers:

• Hodgkin and Non-Hodgkin Lymphoma standard and novel regimens
• Acute and Chronic Leukaemia induction and maintenance chemotherapy
• Acute Promyelocytic Leukaemia ATRA and arsenic-based protocols
• Multiple Myeloma proteasome inhibitors and immunomodulatory agents
• Myeloma and Lymphoma newer biologics and clinical trial protocols

Skin and Rare Cancers

Dr Chanana manages melanoma and rare malignancies:

• Melanoma immunotherapy and BRAF targeted therapy with published educational content
• Neuroendocrine Tumours somatostatin analogue therapy
• Malignant Pleural Mesothelioma systemic management

Qualifications

• MBBS from Maulana Azad Medical College, New Delhi (2010)
• MD Internal Medicine from Lady Hardinge Medical College, New Delhi (2014)
• DM Medical Oncology from Tata Memorial Hospital, Mumbai, Homi Bhabha National Institute (2017)
• ESMO Certification from European Society for Medical Oncology
• Certification in Advanced Management of Oncological Disease, Harvard Medical School, Boston, USA (2025)

Dr Chanana holds active medical council registration with the Delhi Medical Council (Reg. No. 6939, 2011), supporting his current practice as a medical oncologist in Delhi.

Milestones and Clinical Achievements

• Over 16 years of medical oncology practice spanning Tata Memorial Hospital and Narayana Health network
• Director of Medical Oncology at Dharamshila Narayana Superspeciality Hospital, one of Delhi's leading dedicated cancer hospitals
• Active participation in international clinical trials and oncology research at Tata Memorial Hospital during training
• Hosted international oncology academic sessions at Dharamshila Narayana including faculty from Roswell Park Comprehensive Cancer Center, USA on urothelial carcinoma management
• Participated in Cancer Summit Panel on Financing Cancer Treatment as moderator, addressing cancer insurance, NBFCs, and pharma patient assistance programmes
• Active contributor to cancer awareness and public health education through media features in India Today, and LinkedIn health education on topics including oesophageal cancer risk, generic drug safety, and subcutaneous immunotherapy
• Involved in Circulating Tumour Cell (CTC) Tumour Board at Dharamshila Narayana Hospital, advancing liquid biopsy adoption in routine oncology practice

Research and Publications

Dr Chanana has published peer-reviewed research in indexed national and international oncology journals, primarily from his training years at Tata Memorial Hospital:

• Ceritinib in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer among Patients Previously Exposed to Crizotinib: Experience from the Indian Subcontinent, South Asian Journal of Cancer, December 2017
• ROS1 Rearranged Non-Small Cell Lung Cancer and Crizotinib: An Indian Experience, Indian Journal of Cancer, 2017, 54(2): 436 to 438
• Are We There RET, Cancer Research Statistics and Treatment, 2022, 5: 175 to 176
• QOL Analysis of a Phase II Randomized Controlled Clinical Trial Comparing Efficacy of Cabazitaxel versus Docetaxel as Second Line or Above in Recurrent and Metastatic Head and Neck Cancer, ESMO Asia 2017, Poster Presentation
• A Retrospective Cohort Study to Evaluate the Epidemiology and Treatment Outcomes of Advanced Malignant Pleural Mesothelioma Treated in a Tertiary Care Centre from India, JSMO 2018, Kobe, Japan, Poster Presentation

His Narayana Health blog contributions include:

• Lung Cancer Awareness Month: What You Need to Know, Narayana Health Blog, November 2024
• Melanoma (Skin Cancer): Immunotherapy's Impact on Treatment, Narayana Health Blog, July 2024
• Antibody Drug Conjugate (ADC): Role in Managing Advanced Cancers, Narayana Health Blog, June 2024
• Targeted Therapies for Breast Cancer, Narayana Health Blog, May 2024

Professional Memberships

• Delhi Medical Council
• Medical Council of India (MCI)
• Indian Society of Medical and Paediatric Oncology (ISMPO)
• European Society of Medical Oncology (ESMO)
• American Society of Clinical Oncology (ASCO)

Hospital Affiliations in Delhi

Current Practice

• Dharamshila Narayana Superspeciality Hospital, Vasundhara Enclave, Delhi as Senior Consultant and Director Medical Oncology. Consultation Fee: ₹1200
• Oncare Cancer Care Centre, Sector 41, Delhi as Senior Consultant and HOD Medical Oncology. Consultation Fee: ₹1000
• Kalka Superspeciality Clinic, Kalkaji, Delhi as Consultant

Past Experience

• Narayana Superspeciality Hospital, Sector 24, Gurugram as Consultant Medical Oncology (2023 to 2025)
• Tata Memorial Hospital, Mumbai as Specialist Registrar, Department of Medical Oncology (August 2014 to July 2018)

Book an Appointment with Dr Raajit Chanana, Medical Oncologist in Delhi

To check consultation fees and book a priority appointment with Dr Raajit Chanana at Dharamshila Narayana Superspeciality Hospital, Vasundhara Enclave or Oncare Cancer Care Centre, Sector 41, Delhi, visit HexaHealth for a smooth and hassle-free booking experience.